Rheum Palmatum syrup and NAFLD

Phase 2

Recruiting

• Conditions: on-alcoholic fatty liver disease.; K76.0Fatty (change of) liver, not elsewhere classified Nonalcoholic fatty liver disease (NAFLD); K76.0

• Registration Number: IRCT20211019052813N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Age between 18 and 60 years
Fatty liver disease based on high liver enzymes

Exclusion Criteria

Type 1 and type 2 diabetes (requires medication)
Positive serology of viral hepatitis B and C (anti-HCV or HBsAg positive)
Liver and kidney disease
Blood pressure-requiring medication (BP> 85/85 mmhg)
Liver cirrhosis
Pregnancy and lactation
Hyperlipidemia (requires medication TG> 150mg / dl)
Wilson and hemochromatosis
Autoimmune hepatitis
Taking drugs such as valproate, amiodarone, methotrexate, tamoxifen, corticosteroids
Hypothyroidism (requires medication)
Active malignancy in the body

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
iver enzymes (ALT, AST). Timepoint: Baseline, after one month and after three months from the beginning of the study. Method of measurement: Measurement of serum levels of serum enzymes quantitatively.;Body mass index. Timepoint: Baseline, after one month and after three months from the beginning of the study. Method of measurement: weight in kilograms divided by height in meters squared.